Science 37 Wins 2026 BioTech Innovation Award for Clinical Trial Model
Recognized for its pioneering Direct-to-Patient Site model, Science 37 is transforming clinical trial accessibility across the nation.
Innovative Approach to Clinical Trials
Science 37, headquartered in Morrisville, North Carolina, has recently been honored with the title of 'BioTechnology Innovation of the Year' at the 2026 BioTech Breakthrough Awards. This recognition celebrates Science 37’s Direct-to-Patient Site model, which is revolutionizing the way clinical trials are conducted by making them accessible directly to patients in their own homes, independent of their geographical location.
Breaking Down Barriers
For decades, traditional clinical trials have limited participation to individuals who can travel to physical research sites. Science 37 challenges this norm by functioning as a centralized clinical research site that covers the entire United States. This innovative model allows pharmaceutical sponsors to broaden patient engagement in clinical trials without the need to establish an extensive network of local research facilities.
Utilizing expert medical oversight, licensed investigators in every state, and mobile nursing teams, Science 37 delivers clinical research capabilities directly to patients. This approach not only complements existing research sites but also provides an alternative pathway that enhances trial enrollment and maintains patient involvement during the entire research process.
Impactful Outcomes
The influence of Science 37’s approach is supported by independent research from the Tufts Center for the Study of Drug Development. Findings highlight significant advantages:
- Higher Enrollment Rates: Science 37’s average trial enrollment reached 150 participants, a striking contrast to the mere 26 participants typically seen at traditional trial sites.
- Strategic Study Contributions: As a singular research site, Science 37 comprised 20-30% of total enrollment in trials reviewed.
- Enhanced Participant Retention: The organization achieved completion rates over 50% greater than the industry standard.
- Diverse Representation: The analysis revealed improved diversity, with increased participation from women and Black individuals, showcasing the model's effectiveness in engaging underrepresented groups in clinical research.
Proven Performance
Having supported over 200 clinical trials, encompassing all phases and observational studies, Science 37 has executed more than 14,000 in-home visits for clinical evaluations. The company has also undergone five Phase 3 Food and Drug Administration (FDA) inspections, all resulting in a No Action Indicated (NAI) classification with no findings, underscoring its ability to maintain high standards in a compliant and efficient manner.
"Science 37 is redefining the traditional limits of clinical research by demonstrating that location should not hinder patient participation," stated Bryan Vaughn, Managing Director of BioTech Breakthrough. "Their integration of centralized oversight and direct-to-patient services illustrates how innovations can widen the accessibility of critical clinical trials while adhering to rigorous research standards."
As clinical trials grow more complex, Science 37 is committed to further developing its direct-to-patient model across diverse therapeutic areas and study designs, enabling broader and more patient-centric research methodologies.
The goal is clear: Clinical research should be accessible to all, unconstrained by geography. Science 37 is already making strides toward turning this vision into reality.